Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients

被引：0
|
作者：
Orkin, C. [1 ]
Rockstroh, J. [2 ]
DeJesus, E. [3 ]
Henry, K. [4 ]
Molina, J. [5 ]
Gathe, J. [6 ]
Wei, X. [7 ]
Fordyce, M. [7 ]
Rhee, M. [7 ]
Smith, A. [8 ]
Szwarcberg, J. [7 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ Bonn, Bonn, Germany
[3] Orlando Immunol Ctr, Orlando, FL USA
[4] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
[5] St Louis Hosp, Paris, France
[6] Therapeut Concepts PA, Houston, TX USA
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] Gilead Sci Inc, Cambridge, England
来源：
HIV MEDICINE | 2013年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, X.
    Rhee, M.
    Szwarcberg, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [2] Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients
    Orkin, C.
    Clumeck, N.
    Girard, P-M
    Henry, K.
    Gathe, J.
    Rockstroh, J.
    DeJesus, E.
    Yau, S.
    Smith, A.
    Wei, X.
    White, K.
    Fordyce, M.
    Rhee, M.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2014, 15 : 114 - 114
  • [3] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Zolopa, A.
    Gallant, J.
    Cohen, C.
    Sax, P.
    Dejesus, E.
    Mills, A.
    Wohl, D.
    Liu, H.
    Rhee, M.
    Szwarcberg, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [4] Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
    Kulkarni, Rima
    Abram, Michael E.
    McColl, Damian J.
    Barnes, Tiffany
    Fordyce, Marshall W.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    White, Kirsten L.
    [J]. HIV CLINICAL TRIALS, 2014, 15 (05): : 218 - 229
  • [5] Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks
    DeJesus, E.
    Orkin, C.
    Rockstroh, J.
    Molina, J-M
    White, K.
    Wei, X.
    Plummer, A.
    Kearney, B.
    Cheng, A.
    [J]. HIV MEDICINE, 2012, 13 : 9 - 9
  • [6] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects
    Sax, P.
    DeJesus, E.
    Mills, A.
    Zolopa, A.
    Cohen, C.
    Wohl, D.
    Gallant, J.
    Bosse, M.
    White, K.
    Liu, C.
    Plummer, A.
    Kearney, B.
    Quirk, E.
    Cheng, A.
    [J]. HIV MEDICINE, 2012, 13 : 9 - 9
  • [7] Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine
    Quirk, E.
    Graham, H.
    Liu, C.
    Rhee, M.
    Piontkowsky, D.
    Szwarcberg, J.
    [J]. ANTIVIRAL THERAPY, 2013, 18 : A63 - A63
  • [8] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Rockstroh, Juergen K.
    DeJesus, Edwin
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Plummer, Andrew
    Abram, Michael
    Cheng, Andrew K.
    Fordyce, Marshall W.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (05) : 483 - 486
  • [9] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
    White, Kirsten L.
    Kulkarni, Rima
    McColl, Damian J.
    Rhee, Martin S.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    [J]. ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
  • [10] Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48
    Mounzer, K.
    Rashbaum, B.
    Lucasti, C.
    Melbourne, K.
    Kwon, P.
    Nguyen, T.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A26 - A27
12345